FDA Prescription Drug User Fee Rates: Fiscal Year 2019

August 10, 2018

On Wednesday, August 1st, FDA released a notice with updated prescription drug user fee rates for fiscal year 2019.

Prescription Drug Application Fees

According to the Food, Drug, & Cosmetic (FD&C) Act, application fees should provide 20% of the total revenue, while program fees should provide the other 80%. Application fees are set at $202,064,400 for FY 2019. The application fees were determined by estimating the total number of expected fee-paying full application equivalents (FAEs) for the year. The updated fees are as follows:

  • Full application (with clinical data): $2,588,478
  • Application (without clinical data): $1,294,239

This is a 6.9% increase from FY 2018 fees, which were $2,421,495 per full application requiring clinical data, and $1,210,748 per application not requiring clinical data.

Prescription Drug Program Fees

FY 2019 program fees were calculated by dividing the adjusted total revenue from program fees ($808,257,600) by the estimated number of program fees (2,608). The FY 2019 program fee is $309,915. This is a 1.9 percent increase from the FY 2018 program fee of $304,162.

Fee Category FY 2019 Fee Rates FY 2018 Fee Rates
Application Requiring Clinical Data $2,588,478 $2,421,495
Application Not Requiring Clinical Data $1,294,239 $1,210,748
Program $309,915 $304,162

We can help you get your product approved by the FDA in less time and for less money. Using our proprietary approach which combines scientific knowledge with regulatory expertise, we have helped countless clients achieve successful outcomes with FDA. To learn more about our services and how we can help you, contact us today.

TAGS:

November 11, 2014

FDA Prepares for GDUFA Commitments with Controlled Correspondence Guidance

With the implementation of GDUFA, FDA defined the rules and specific protocol for submitting controlled correspondence to the Office of Generic Drugs (OGD) in a draft guidance published on August 27,...

How GDUFA II Impacts the Timing and Approval Process for Generic Drug Sponsors

How GDUFA II Impacts the Timing and Approval Process for Generic Drug Sponsors: Facing several regulatory challenges related to the review of abbreviated new drug applications (ANDAs), Congress first...

March 31, 2015

Drug Development Questions And The FDA - The End Of The Black Hole

Commonly during drug development, significant issues arise for which FDA input is desired but that do not merit a full face-to-face multidisciplinary milestone meeting. In many cases, sponsors are...